These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16400314)

  • 41. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Vennegoor A; Wattjes MP; van Munster ET; Kriekaart RL; van Oosten BW; Barkhof F; Killestein J; Polman CH
    Neurology; 2011 Feb; 76(6):574-6. PubMed ID: 21300973
    [No Abstract]   [Full Text] [Related]  

  • 42. Lessons from the clinic: a case of natalizumab-associated PML.
    Clifford DB
    Neurology; 2011 Feb; 76(6):574. PubMed ID: 21300972
    [No Abstract]   [Full Text] [Related]  

  • 43. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S; Berger JR
    J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F; Chiarini M; Sottini A; Bertoli D; Giustini V; Tessitore MV; Caimi L; Capra R; Imberti L
    J Neuroimmunol; 2014 Dec; 277(1-2):6-12. PubMed ID: 25468273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
    Hoepner R; Ahlbrecht J; Faissner S; Schneider R; Dahlhaus S; Adams O; Raab P; Lukas C; Chan A; Stangel M; Gold R
    J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1177-8. PubMed ID: 24700881
    [No Abstract]   [Full Text] [Related]  

  • 47. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natalizumab.
    Berger JR
    Drugs Today (Barc); 2006 Oct; 42(10):639-55. PubMed ID: 17136224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comments on "first-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis".
    Zhang H; Pan W; Ji W
    Neurol Sci; 2014 Jun; 35(6):959. PubMed ID: 24554420
    [No Abstract]   [Full Text] [Related]  

  • 51. Therapeutic developments in MS: report from the 57th Annual Meeting of the American Academy of Neurology (AAN), 9-15 April 2004, Miami, Florida, USA.
    Clanet M
    Int MS J; 2005 Aug; 12(2):69-70. PubMed ID: 16417817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The trials and tribulations of Tysabri.
    Lancet Neurol; 2006 May; 5(5):373. PubMed ID: 16632299
    [No Abstract]   [Full Text] [Related]  

  • 53. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective treatment of multiple sclerosis.
    Ropper AH
    N Engl J Med; 2006 Mar; 354(9):965-7. PubMed ID: 16510751
    [No Abstract]   [Full Text] [Related]  

  • 56. Natalizumab and progressive multifocal leucoencephalopathy.
    Berger JR
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii48-53. PubMed ID: 17038473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurologic indications for therapeutic plasma exchange: 2011 update.
    Gwathmey K; Balogun RA; Burns T
    J Clin Apher; 2012; 27(3):138-45. PubMed ID: 22522566
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
    Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
    Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Demyelination as a complication of new immunomodulatory treatments.
    Lysandropoulos AP; Du Pasquier RA
    Curr Opin Neurol; 2010 Jun; 23(3):226-33. PubMed ID: 20442571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How Tysabri survived.
    Huggett B
    Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.